News | May 19, 2022
Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
This new fund is amongst the largest for the sector in India
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
It is developing the drug candidate to potentially treat immunological diseases
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
The drug will be available in 600 hospitals and 105 DTPs
Subscribe To Our Newsletter & Stay Updated
